This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: The Brigham and Women's Hospital, Inc.. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Rafael Kramann: Innovator in Fibrosis Detection and Treatment
Introduction
Rafael Kramann is a notable inventor based in Lemiers, Netherlands. He has made significant contributions to the field of medical research, particularly in the detection and treatment of tissue fibrosis. His innovative work has the potential to improve patient outcomes by enabling early diagnosis and intervention.
Latest Patents
Kramann holds a patent titled "Uses of GLI1 in detecting tissue fibrosis." This patent outlines methods for using Gli-1 as a specific marker for myofibroblast progenitor cells. This advancement allows for the diagnosis of early stages of fibrosis before the onset of organ failure. Additionally, the patent includes methods for isolating Gli-1+ cells, which can be utilized in high-throughput screening of compounds aimed at treating or preventing fibrosis. Furthermore, the patent describes methods for treating or preventing fibrosis, such as kidney fibrosis, by administering a Gli inhibitor, particularly a Gli-2 inhibitor or a Gli-1/Gli-2 inhibitor.
Career Highlights
Kramann is affiliated with The Brigham and Women's Hospital, Inc., where he continues to advance his research in fibrosis. His work is characterized by a commitment to improving diagnostic techniques and therapeutic strategies in the medical field.
Collaborations
Kramann collaborates with esteemed colleagues, including Derek Dirocco and Benjamin D Humphreys. These partnerships enhance the scope and impact of his research, fostering innovation in the study of fibrosis.
Conclusion
Rafael Kramann's contributions to the field of fibrosis detection and treatment exemplify the importance of innovation in medical research. His patent on Gli-1 as a marker for fibrosis represents a significant step forward in early diagnosis and therapeutic intervention.